FY2028 EPS Estimates for Insulet Boosted by Leerink Partnrs

Insulet Co. (NASDAQ:PODD) – Stock analysts at Leerink Partnrs raised their FY2028 EPS estimates for shares of Insulet in a report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the medical instruments supplier will post earnings per share of $7.80 for the year, up from their previous estimate of $7.75. The consensus estimate for Insulet’s current full-year earnings is $3.22 per share.

Other research analysts have also recently issued reports about the stock. Raymond James raised their price objective on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. Sanford C. Bernstein initiated coverage on Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target for the company. UBS Group increased their price objective on Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Piper Sandler lifted their price objective on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Finally, BTIG Research upped their target price on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $253.27.

Insulet Stock Performance

Shares of PODD opened at $266.92 on Wednesday. Insulet has a 12-month low of $160.19 and a 12-month high of $279.40. The stock has a market cap of $18.72 billion, a P/E ratio of 45.70, a PEG ratio of 4.08 and a beta of 1.22. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The company has a 50-day moving average of $242.59 and a two-hundred day moving average of $212.36.

Hedge Funds Weigh In On Insulet

Large investors have recently bought and sold shares of the stock. Motley Fool Asset Management LLC raised its position in shares of Insulet by 7.1% in the 1st quarter. Motley Fool Asset Management LLC now owns 1,397 shares of the medical instruments supplier’s stock worth $239,000 after buying an additional 93 shares during the period. Tidal Investments LLC raised its holdings in shares of Insulet by 58.8% in the 1st quarter. Tidal Investments LLC now owns 4,064 shares of the medical instruments supplier’s stock worth $697,000 after purchasing an additional 1,504 shares during the period. iA Global Asset Management Inc. acquired a new position in shares of Insulet in the 1st quarter valued at about $105,000. Plato Investment Management Ltd grew its holdings in shares of Insulet by 1,574.0% during the 1st quarter. Plato Investment Management Ltd now owns 6,060 shares of the medical instruments supplier’s stock worth $1,039,000 after purchasing an additional 5,698 shares during the period. Finally, Swedbank AB acquired a new stake in Insulet during the 1st quarter worth approximately $6,903,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.